Ropinirole and pramipexole
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Ropinirole and pramipexole (brand names Requip, Mirapex) — Antiparkinson, restless legs agent; Nonergot dopamine agonists.
Identification
- Therapeutic class: Antiparkinson, restless legs agent.
- Pharmacologic class: Nonergot dopamine agonists.
Pharmacology
- Mechanism of action: Directly stimulate dopamine receptors.
- Onset / peak / duration: Effect over titration; ER once daily.
- Half-life / therapeutic level: Ropinirole about 6 hours, pramipexole about 8 to 12 hours; level not routine.
Clinical use
- Indications: Parkinson disease, restless legs syndrome.
- Usual dose, route, frequency: Titrated PO; pramipexole reduced in renal impairment.
- Maximum dose / adjustments: Titrate slowly; taper to stop.
Safety
- Contraindications: Hypersensitivity.
- Black box warning: None.
- Interactions: Dopamine antagonists oppose effect, CNS depressants.
- Pregnancy / lactation: Use only if essential.
- High-alert: No.
Adverse effects
- Common side effects: Nausea, dizziness, somnolence.
- Serious effects to report: Sudden sleep attacks, impulse-control disorders, orthostatic hypotension, hallucinations.
- Antidote / reversal: None.
Nursing process
- Assessment before administration: Motor and mental status, blood pressure, renal function (pramipexole).
- Interventions during therapy: Caution driving; screen for impulse behaviors.
- Monitor: Motor function, mood and behavior, blood pressure.
- Evaluation / expected outcome: Improved motor symptoms or restless legs.
Patient teaching
- Patient teaching: Report falling asleep suddenly or new compulsive behaviors.
- Notify provider if: Sleep attacks, gambling or other impulses, hallucinations.
- Administration tips: Titrate slowly; taper to discontinue.